Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiol TherapeuticsSTU:CT9 +5.39%36 EV-to-EBITDA is -7.82 as of Aug. 19, 2026. GuruFocus rates STU:CT9 with a GF Score™ of 36/100. The stock has 4 warning signs investors should review. Among 734 Drug Manufacturers companies, Cardiol Therapeutics ranks worse than 136239.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cardiol Therapeutics's enterprise value is €173.62 Mil.
Cardiol Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-22.22 Mil. Therefore, Cardiol Therapeutics's EV-to-EBITDA for today is -7.82.
The historical rank and industry rank for Cardiol Therapeutics's EV-to-EBITDA or its related term are showing as below:
STU:CT9'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.8 Med: -0.67 Max: 0.91
Current: -7.8
During the past 9 years, the highest EV-to-EBITDA of Cardiol Therapeutics was 0.91. The lowest was -7.80. And the median was -0.67.
STU:CT9's EV-to-EBITDA is ranked worse than 100% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs STU:CT9: -7.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cardiol Therapeutics's PE Ratio (TTM) for today is calculated as:
Cardiol Therapeutics's share price for today is €1.602.
Cardiol Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.211.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cardiol Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's EV-to-EBITDA falls into.
Cardiol Therapeutics's current Enterprise Value is €173.62 Mil.
Cardiol Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-22.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiol Therapeutics (STU:CT9) has a EV-to-EBITDA of -7.82 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cardiol Therapeutics. According to the industry distribution chart, Cardiol Therapeutics ranks #999999 out of 734 companies in the Drug Manufacturers industry.
Is Cardiol Therapeutics' EV-to-EBITDA too high?
Cardiol Therapeutics' current EV-to-EBITDA is -7.82. Based on the distribution chart, Cardiol Therapeutics ranks #999999 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #999999 out of 734 companies for EV-to-EBITDA. This places Cardiol Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cardiol Therapeutics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current EV-to-EBITDA is -7.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current EV-to-EBITDA of -7.82. The current EV-to-EBITDA is -7.82. Cardiol Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current EV-to-EBITDA is -7.82 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
36GF Score
Get the complete analysis for STU:CT9
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CT9 has been successfully added to your 
